Cargando…

Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases

Background: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease that can affect patients’ quality of life. Dupilumab is the first biologic agent approved for the treatment of patients with inadequately controlled moderate-to-severe AD and its mechanism of action is based on the i...

Descripción completa

Detalles Bibliográficos
Autores principales: Foti, Caterina, Romita, Paolo, Ambrogio, Francesca, Manno, Carlo, Filotico, Raffaele, Cassano, Nicoletta, Vena, Gino Antonio, De Marco, Aurora, Cazzato, Gerardo, Mennuni, Biagina Gisella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785101/
https://www.ncbi.nlm.nih.gov/pubmed/36556367
http://dx.doi.org/10.3390/life12122002
_version_ 1784857966810234880
author Foti, Caterina
Romita, Paolo
Ambrogio, Francesca
Manno, Carlo
Filotico, Raffaele
Cassano, Nicoletta
Vena, Gino Antonio
De Marco, Aurora
Cazzato, Gerardo
Mennuni, Biagina Gisella
author_facet Foti, Caterina
Romita, Paolo
Ambrogio, Francesca
Manno, Carlo
Filotico, Raffaele
Cassano, Nicoletta
Vena, Gino Antonio
De Marco, Aurora
Cazzato, Gerardo
Mennuni, Biagina Gisella
author_sort Foti, Caterina
collection PubMed
description Background: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease that can affect patients’ quality of life. Dupilumab is the first biologic agent approved for the treatment of patients with inadequately controlled moderate-to-severe AD and its mechanism of action is based on the inhibition of the interleukin (IL)-4 and IL-13 signaling. There are only a few data on the safety of dupilumab in AD patients with comorbidities, including kidney disorders. Materials and Methods: Descriptive retrospective series of three patients with chronic kidney diseases (Alport syndrome, IgA nephropathy, and hypertensive nephrosclerosis, respectively) receiving dupilumab for their concomitant severe AD. Results: Treatment with a standard dosage of dupilumab caused a relevant improvement of AD in all patients without any adverse events or worsening of renal function. In a patient with severe renal failure, the drug was effective and well tolerated without the need for any dose adjustments, also after the initiation of peritoneal dialytic treatment. Conclusion: Our case series suggests the use of dupilumab as an effective and safe treatment for AD patients suffering from renal diseases, although additional studies are required to confirm such preliminary findings.
format Online
Article
Text
id pubmed-9785101
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97851012022-12-24 Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases Foti, Caterina Romita, Paolo Ambrogio, Francesca Manno, Carlo Filotico, Raffaele Cassano, Nicoletta Vena, Gino Antonio De Marco, Aurora Cazzato, Gerardo Mennuni, Biagina Gisella Life (Basel) Case Report Background: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease that can affect patients’ quality of life. Dupilumab is the first biologic agent approved for the treatment of patients with inadequately controlled moderate-to-severe AD and its mechanism of action is based on the inhibition of the interleukin (IL)-4 and IL-13 signaling. There are only a few data on the safety of dupilumab in AD patients with comorbidities, including kidney disorders. Materials and Methods: Descriptive retrospective series of three patients with chronic kidney diseases (Alport syndrome, IgA nephropathy, and hypertensive nephrosclerosis, respectively) receiving dupilumab for their concomitant severe AD. Results: Treatment with a standard dosage of dupilumab caused a relevant improvement of AD in all patients without any adverse events or worsening of renal function. In a patient with severe renal failure, the drug was effective and well tolerated without the need for any dose adjustments, also after the initiation of peritoneal dialytic treatment. Conclusion: Our case series suggests the use of dupilumab as an effective and safe treatment for AD patients suffering from renal diseases, although additional studies are required to confirm such preliminary findings. MDPI 2022-11-30 /pmc/articles/PMC9785101/ /pubmed/36556367 http://dx.doi.org/10.3390/life12122002 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Foti, Caterina
Romita, Paolo
Ambrogio, Francesca
Manno, Carlo
Filotico, Raffaele
Cassano, Nicoletta
Vena, Gino Antonio
De Marco, Aurora
Cazzato, Gerardo
Mennuni, Biagina Gisella
Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases
title Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases
title_full Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases
title_fullStr Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases
title_full_unstemmed Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases
title_short Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases
title_sort treatment of severe atopic dermatitis with dupilumab in three patients with renal diseases
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785101/
https://www.ncbi.nlm.nih.gov/pubmed/36556367
http://dx.doi.org/10.3390/life12122002
work_keys_str_mv AT foticaterina treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases
AT romitapaolo treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases
AT ambrogiofrancesca treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases
AT mannocarlo treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases
AT filoticoraffaele treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases
AT cassanonicoletta treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases
AT venaginoantonio treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases
AT demarcoaurora treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases
AT cazzatogerardo treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases
AT mennunibiaginagisella treatmentofsevereatopicdermatitiswithdupilumabinthreepatientswithrenaldiseases